Skip to content

Enterprise Investment Scheme

Madeleine Ingram, Calculus Capital, London, 25 August 2015. Calculus Capital is the focus of this article on how the UK’s Enterprise Investment Scheme landscape is shifting and where Calculus Capital sits in the new EIS market. By Tom Burroughes. In the first part of a feature examining the views of practitioners within the … Continued

Biotech outfit Synpromics gets £2.1m cash injection

Calculus Capital’s investment in Synpromics was featured in The Scotsman: An Edinburgh based biotech firm that is helping to find cures for haemophilia and hereditary blindness has secured a £2.1 million investment to develop its gene therapies. Synpromics, based at the city’s BioQuarter life sciences incubator, received the cash injection from private equity firm Calculus Capital, which … Continued

Calculus Capital invests in Synpromics

Private equity fund manager Calculus Capital has invested £2.1m in Synpromics, a Scottish-based synthetic biology company. The funds will be used for business expansion and further development of Synpromics’ proprietary synthetic promoter technology. Synpromics is a privately backed synthetic biology business with unique IP and know-how in the development and application of synthetic promoters. Synthetic promoters … Continued